Neonatal Hypoglycemia

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made based on individual patient circumstances, local protocols, and the clinician's judgment. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to patient care.

Overview

• Definition: Neonatal hypoglycemia is a common metabolic disturbance in newborns, characterized by abnormally low plasma glucose concentrations. While there is no universally accepted single cut-off, clinically significant hypoglycemia is often defined by glucose levels below certain thresholds, particularly in at-risk infants, that can lead to neurodevelopmental impairment. Current functional thresholds for intervention in at-risk infants are often cited as plasma glucose < 40-50 mg/dL (2.2-2.8 mmol/L) within the first 24-48 hours of life, or symptomatic hypoglycemia at any level.

• Epidemiology:

  • Incidence: It is one of the most common metabolic problems in the neonatal period, affecting approximately 1-5 per 1,000 live births in healthy term infants, but significantly higher (up to 30-50%) in at-risk populations.
  • Demographics: Higher incidence in infants of diabetic mothers (IDM), preterm infants, small for gestational age (SGA), large for gestational age (LGA), and infants experiencing perinatal stress (e.g., asphyxia, sepsis).

• Classification:

  • By Onset:
    • Early-onset (Transient): Most common, typically resolves within the first 72 hours of life. Often due to inadequate glucose production, excessive glucose utilization, or both, in the context of perinatal stress or poor adaptation. Examples include IDM, LGA, prematurity, asphyxia.
    • Late-onset (Persistent/Recurrent): Persists beyond 72 hours or recurs frequently. Often indicative of a more serious underlying pathology such as congenital hyperinsulinism, inherited metabolic disorders, or endocrine deficiencies.
  • By Cause:
    • Increased Glucose Utilization: Hyperinsulinism (e.g., IDM, Beckwith-Wiedemann syndrome, Nesidioblastosis/Congenital Hyperinsulinism), polycythemia, sepsis, hypothermia, increased work of breathing.
    • Decreased Glucose Production/Stores: Prematurity, SGA, intrauterine growth restriction (IUGR), perinatal asphyxia, glycogen storage diseases, gluconeogenesis defects.
    • Endocrine Deficiencies: Hypopituitarism (e.g., growth hormone deficiency, ACTH deficiency), adrenal insufficiency, hypothyroidism.

Pathophysiology

• Mechanism: Normal neonatal glucose homeostasis involves a complex interplay of glucose production (glycogenolysis, gluconeogenesis) and utilization, primarily regulated by insulin and counter-regulatory hormones (glucagon, cortisol, growth hormone, epinephrine).

  • Post-birth adaptation: Immediately after birth, the neonate transitions from continuous maternal glucose supply to independent glucose regulation. Glycogen stores, especially in the liver, are mobilized, and gluconeogenesis begins.
  • Imbalance leading to hypoglycemia:
    • Inadequate glucose supply/production: Depleted glycogen stores (e.g., prematurity, SGA), impaired gluconeogenesis (e.g., inherited metabolic disorders), insufficient exogenous intake (e.g., poor feeding, inadequate breast milk supply).
    • Increased glucose utilization: Hyperinsulinism (either transient due to maternal diabetes or persistent congenital forms), increased metabolic demand (e.g., sepsis, hypothermia, respiratory distress, polycythemia).
    • Hormonal imbalances: Deficiency of counter-regulatory hormones (e.g., cortisol, growth hormone) or excess of insulin.

• Risk Factors:

  • Maternal Factors:
    • Diabetes (gestational or pre-existing): Leads to fetal hyperinsulinemia.
    • Hypertension/Preeclampsia: Often associated with SGA.
    • Maternal medications: Beta-blockers, oral hypoglycemic agents.
    • Intravenous glucose administration to mother during labor (can cause rebound neonatal hypoglycemia).
  • Neonatal Factors:
    • Prematurity: Inadequate glycogen stores, immature enzyme systems.
    • Small for Gestational Age (SGA)/IUGR: Reduced glycogen stores, increased metabolic demands.
    • Large for Gestational Age (LGA): Often associated with maternal diabetes leading to fetal hyperinsulinemia.
    • Infants of Diabetic Mothers (IDM): Fetal hyperinsulinemia in response to maternal hyperglycemia.
    • Perinatal Stress: Asphyxia, hypothermia, sepsis, respiratory distress syndrome (RDS), meconium aspiration syndrome (MAS), polycythemia (increased glucose consumption by red blood cells).
    • Congenital Anomalies: Beckwith-Wiedemann syndrome, congenital heart disease, central nervous system abnormalities.
    • Inborn Errors of Metabolism: Glycogen storage diseases, fatty acid oxidation defects, organic acidemias, amino acid disorders.
    • Endocrine Deficiencies: Congenital hypopituitarism, adrenal insufficiency.

• Protective Factors:

  • Early and frequent initiation of feeding (breast milk or formula).
  • Adequate caloric intake.
  • Maintenance of normothermia (prevention of cold stress).
  • Skin-to-skin contact, especially for breastfed infants.
  • Effective management of maternal diabetes during pregnancy and labor.

Clinical Presentation

Signs and Symptoms

Neonatal hypoglycemia can be asymptomatic, particularly in the early stages or with milder hypoglycemia. When symptoms occur, they are often non-specific.

• Cardinal Features:

  • Jitteriness/Tremors
  • Lethargy/Hypotonia
  • Poor feeding/Suckling difficulties
  • Irritability or high-pitched cry

• Early Signs:

  • Temperature instability (especially hypothermia)
  • Tachypnea or irregular breathing
  • Apneic spells
  • Vomiting
  • Pallor or cyanosis

• Advanced Signs:

  • Seizures (focal or generalized)
  • Coma or unresponsiveness
  • Bradycardia
  • Stupor
  • Abnormal posturing

• Atypical Presentations:

  • Some neonates, even with significant hypoglycemia, may remain asymptomatic. This highlights the importance of targeted screening in at-risk populations.
  • Subtle changes in behavior or feeding patterns may be the only initial clue.

Physical Examination

• Inspection:

  • Observe for general activity level: lethargy, jitteriness, tremors, hypotonia, abnormal movements (seizures).
  • Skin color: pallor, cyanosis, mottling.
  • Breathing pattern: tachypnea, irregular breathing, apnea.
  • Presence of birth trauma or congenital anomalies.

• Palpation:

  • Temperature assessment: Hypothermia is common.
  • Peripheral perfusion: Capillary refill time, warmth of extremities (can be poor).
  • Fontanelle: May be depressed if dehydrated, not directly related to hypoglycemia but can coexist.

• Special Tests: No specific "special tests" for direct diagnosis of hypoglycemia via physical exam. Neurological assessment is crucial in symptomatic infants to evaluate for signs of cerebral dysfunction.

Diagnostic Approach

History Taking

• Key Questions:

  • Maternal History: Gestational diabetes, pre-existing diabetes, hypertension/preeclampsia, maternal medications (e.g., beta-blockers), maternal IV glucose during labor.
  • Birth History: Gestational age, birth weight (SGA, LGA), Apgar scores, presence of perinatal asphyxia, meconium aspiration, polycythemia, need for resuscitation.
  • Feeding History: Time of first feed, frequency and quantity of feeds (breast vs. formula), evidence of poor latch/suck, vomiting.
  • Current Symptoms: Detailed description of observed signs (jitteriness, lethargy, poor feeding, temperature instability, seizures) and their onset, duration, and frequency.
  • Family History: History of neonatal deaths, unexplained hypoglycemia, endocrine disorders, consanguinity.

• Red Flags:

  • Any neurological symptoms (seizures, profound lethargy, abnormal posturing).
  • Persistent or recurrent hypoglycemia despite adequate glucose infusion.
  • Hypoglycemia requiring high glucose infusion rates (>10-12 mg/kg/min).
  • Hypoglycemia in a term, healthy, appropriately grown infant without obvious risk factors (suggests underlying pathology).
  • Hypoglycemia accompanied by other signs of metabolic derangement (e.g., metabolic acidosis, hyperammonemia, unusual odor).

Laboratory Tests

• First-Line:

  • Capillary Blood Glucose Screening: Obtained via heel stick.
    • At-risk infants: Screen before the first feed and then every 3-6 hours for at least 24-48 hours, or until glucose levels are stable and within the normal range.
    • Target Thresholds for Intervention (AAP 2011 recommendations and common practice):
      • First 4 hours of life: < 25-30 mg/dL (1.4-1.7 mmol/L)
      • 4-24 hours of life: < 35-40 mg/dL (1.9-2.2 mmol/L)
      • Target for stable glucose: Aim for >45-50 mg/dL (2.5-2.8 mmol/L) before routine feeds. For asymptomatic at-risk infants after 24 hours of age, a glucose >45 mg/dL is generally considered acceptable.
    • Note: Point-of-care (POC) devices are screening tools and require venous confirmation if an abnormal value is obtained.
  • Venous Plasma Glucose: Mandatory for confirmation of any low capillary glucose reading, especially if symptomatic, or if the value is at or below the intervention threshold. This is the definitive diagnostic test.

• Confirmatory (for persistent/recurrent hypoglycemia or to investigate underlying cause):

  • Critical Sample: If hypoglycemia persists, collect a "critical sample" (venous blood drawn at the time of hypoglycemia before glucose administration) for:
    • Insulin and C-peptide levels: Elevated in hyperinsulinism.
    • Cortisol and Growth Hormone levels: To evaluate for adrenal insufficiency or hypopituitarism.
    • Beta-hydroxybutyrate (ketones) and Free Fatty Acids: Low or absent in hyperinsulinism (suppressed lipolysis/ketogenesis), elevated in disorders of gluconeogenesis or glycogenolysis.
    • Lactate, Pyruvate, Ammonia, Amino Acids, Organic Acids: To screen for inborn errors of metabolism.
  • Electrolytes: To assess hydration and potential electrolyte imbalances.
  • Liver function tests: For liver dysfunction or glycogen storage diseases.

• Monitoring:

  • Serial blood glucose measurements (capillary or venous) every 1-3 hours until glucose is stable and within desired range for at least 24 hours, and the infant is consistently feeding well.
  • Reduce monitoring frequency as stability is achieved, but continue for at least 24-48 hours after IV glucose is discontinued or after the last hypoglycemic event.

Imaging

• Recommended: No routine imaging is recommended for the diagnosis of neonatal hypoglycemia itself.

• Advanced:

  • Cranial Ultrasound or MRI Brain: Indicated in symptomatic infants (e.g., with seizures) to assess for potential brain injury (e.g., hypoxic-ischemic encephalopathy, stroke) or structural brain anomalies (e.g., pituitary hypoplasia in cases of hypopituitarism).
  • Abdominal Ultrasound/CT/MRI: Rarely indicated for persistent hyperinsulinism to locate an insulinoma, though diffuse pancreatic involvement is more common in congenital hyperinsulinism.

Management

Acute Management

• Immediate (First-hour interventions):

  1. For asymptomatic at-risk infants with a blood glucose below the intervention threshold:
     • Immediately initiate or increase feeding (breast milk or formula). Aim for adequate caloric intake.
     • Recheck glucose in 30-60 minutes.
     • If glucose remains low or infant becomes symptomatic, proceed to IV dextrose.
  2. For symptomatic infants or any infant with critical low glucose (<20-25 mg/dL / 1.1-1.4 mmol/L):
     • Stat IV Glucose Bolus: Administer Dextrose 10% in water (D10W) 2 mL/kg IV push over 1-2 minutes. (Provides 200 mg/kg of glucose).
     • Immediately follow with a continuous intravenous dextrose infusion.
     • Ensure IV access is patent and secure.
     • Keep infant warm and dry.
     • Monitor vital signs.

• Stabilization (Early management priorities):

  • Continuous IV Dextrose Infusion:
    • Start with D10W at a glucose infusion rate (GIR) of 6-8 mg/kg/min.
    • Calculation: GIR (mg/kg/min) = [Dextrose concentration (%) x Infusion Rate (mL/hr) x 10] / (Weight (kg) x 60).
    • Monitor blood glucose every 1-2 hours after initiation/change in GIR until stable above target for at least 2 consecutive readings.
    • Adjust GIR as needed, increasing by 1-2 mg/kg/min increments if glucose remains low, up to a maximum of 12-15 mg/kg/min for transient hypoglycemia.
    • If IV access is difficult, intramuscular glucagon (0.03-0.1 mg/kg, max 1 mg) can be considered as a temporary measure in infants with adequate glycogen stores (e.g., IDM, LGA). This is a bridge, not a definitive solution.

• Emergency (Crisis management):

  • For severe hypoglycemia with neurological symptoms (e.g., seizures), immediate D10W bolus (2 mL/kg) is critical, followed by continuous infusion.
  • Secure airway if necessary, provide respiratory support.
  • Address other contributing factors (e.g., hypothermia, sepsis, respiratory distress).

Chronic Management (for persistent/recurrent hypoglycemia)

• Pharmacological:

  • Diazoxide: Oral medication, typically for congenital hyperinsulinism. It inhibits insulin secretion. Initial dose 5-10 mg/kg/day divided q8-12h, titrate up to 15-20 mg/kg/day. Side effects: fluid retention, hypertrichosis.
  • Octreotide: Somatostatin analog, inhibits insulin release. Given subcutaneously. Dose varies, typically 5-25 mcg/kg/day divided q6-8h. Reserved for cases unresponsive to diazoxide or as bridge to surgery.
  • Glucagon: Can be used via continuous infusion for specific types of hyperinsulinism or metabolic disorders, but less effective long-term if glycogen stores are depleted.
  • Hydrocortisone: For adrenal insufficiency. Dose: 5 mg/kg/day (stress dose) then 1-2 mg/kg/day.
  • Growth Hormone (GH) Supplementation: For GH deficiency.
  • Carnitine or specific enzyme replacement/cofactors: For certain inborn errors of metabolism.

• Non-pharmacological:

  • Frequent/Continuous Feeds: Nasogastric or orogastric tube feeds to provide constant glucose supply, especially for infants with high caloric needs or feeding difficulties.
  • Dietary Modifications: For some inborn errors of metabolism, specific dietary adjustments (e.g., high-starch, low-fat diets) may be required.
  • Surgical: Partial or near-total pancreatectomy may be necessary for severe, medically refractory congenital hyperinsulinism.

• Monitoring:

  • Long-term glucose monitoring: Continuous glucose monitoring (CGM) or frequent point-of-care checks to ensure euglycemia.
  • Neurodevelopmental follow-up: Essential for all infants with significant or prolonged hypoglycemia, or those who experienced symptomatic episodes. Assess cognitive, motor, language development regularly.
  • Growth monitoring: Ensure adequate weight gain and growth velocity.
  • Follow-up with specialists: Pediatric endocrinology, metabolism, neurology as appropriate.

Treatment Algorithms

• First-Line (Initial approach for at-risk asymptomatic neonates):

  1. Screen blood glucose at 1-2 hours of life and before feeds for the first 24-48 hours.
  2. If blood glucose is 25-40 mg/dL (1.4-2.2 mmol/L) in the first 4 hours, or 35-45 mg/dL (1.9-2.5 mmol/L) in 4-24 hours: Initiate immediate feeding (breast milk or formula). Recheck glucose in 30-60 min.
  3. If blood glucose remains low after feeding, or drops below 25 mg/dL (1.4 mmol/L) at any time, or infant becomes symptomatic: Administer IV D10W bolus 2 mL/kg, followed by IV D10W infusion at 6-8 mg/kg/min.

• Second-Line (For persistent or refractory transient hypoglycemia):

  1. Increase IV glucose infusion rate by 1-2 mg/kg/min increments up to 12-15 mg/kg/min, or as tolerated (consider central line if very high rates needed).
  2. Ensure adequate caloric intake from enteral feeds alongside IV fluids.
  3. Investigate underlying causes (sepsis, metabolic disorders, endocrine deficiencies) if not already done.
  4. Consider hydrocortisone if adrenal insufficiency is suspected or ruled out (e.g., stress dose for overwhelming sepsis).

• Refractory Cases (Indicating likely persistent hypoglycemia):

  1. Glucose infusion rate >10-12 mg/kg/min needed to maintain euglycemia.
  2. Referral to pediatric endocrinology and/or metabolism specialist.
  3. Perform comprehensive diagnostic workup (critical sample for insulin, C-peptide, cortisol, GH, fatty acids, ketones, metabolic screen).
  4. Consider pharmacologic agents like diazoxide or octreotide for hyperinsulinism.
  5. Evaluate for need for partial or near-total pancreatectomy if severe congenital hyperinsulinism is confirmed and medically refractory.

Complications

• Common:

  • Recurrence of hypoglycemic episodes.
  • Difficulty weaning off IV glucose.

• Serious:

  • Neurodevelopmental Impairment: The most significant long-term complication. Can manifest as:
    • Cognitive deficits (learning disabilities, intellectual disability).
    • Motor deficits (cerebral palsy, gross and fine motor delays).
    • Seizure disorder.
    • Visual impairment.
    • Behavioral problems.
  • Seizures: Direct consequence of severe neuroglycopenia.
  • Brain injury (white matter injury, neuronal necrosis, atrophy), particularly in the occipital lobes and hippocampus.

• Long-term:

  • Increased risk for neurodevelopmental delays, particularly if hypoglycemia was severe, prolonged, symptomatic, or recurrent, and especially if underlying etiology (e.g., hyperinsulinism) was present.
  • Need for ongoing medical management for underlying causes (e.g., medication for hyperinsulinism, hormone replacement).

Prognosis

• Factors Affecting Outcome:

  • Severity and Duration: More severe and prolonged episodes (especially >6-12 hours) are associated with worse neurological outcomes.
  • Presence of Symptoms: Symptomatic hypoglycemia, particularly with seizures, carries a higher risk of long-term neurodevelopmental deficits.
  • Underlying Etiology: Hypoglycemia due to hyperinsulinism (especially congenital hyperinsulinism) is associated with a higher risk of brain damage due to suppressed ketone body production (alternative fuel for the brain) during hypoglycemia. Hypoglycemia associated with asphyxia also has a poor prognosis due to combined insults. Transient hypoglycemia in IDM generally has a good prognosis if promptly treated.
  • Promptness and Adequacy of Treatment: Early detection and prompt, effective treatment significantly improve outcomes.

• Survival: Generally high if prompt medical intervention occurs. Mortality is usually related to the underlying cause (e.g., severe sepsis, congenital heart disease, severe metabolic disorder) rather than the hypoglycemia itself, unless it leads to irreversible brain damage.

• Quality of Life: Can be significantly impacted by neurodevelopmental sequelae. Lifelong support and intervention may be required for individuals with severe cognitive or motor impairments.

Prevention

• Primary (Preventing initial occurrence):

  • Optimizing Maternal Glucose Control: Strict glycemic control in diabetic mothers during pregnancy and labor.
  • Early and Frequent Feeding: Encourage breastfeeding or formula feeding within the first hour of life, especially for at-risk infants.
  • Maintain Normothermia: Prevent cold stress, which increases glucose consumption.
  • Avoidance of Unnecessary Glucose Infusion in Mother during Labor: Can lead to rebound neonatal hypoglycemia.

• Secondary (Early detection and intervention):

  • Targeted Screening: Implement robust glucose screening protocols for all at-risk neonates (e.g., IDM, SGA, LGA, preterm, stressed infants) as outlined in the "Diagnostic Approach" section.
  • Prompt Management: Immediate intervention upon detection of low blood glucose, following established protocols.

• Tertiary (Preventing complications):

  • Aggressive Treatment: Treat hypoglycemia promptly and effectively to restore and maintain euglycemia.
  • Identify and Treat Underlying Cause: Crucial for persistent or recurrent hypoglycemia to prevent ongoing neuroglycopenia.
  • Neurodevelopmental Surveillance: Regular follow-up and early intervention programs for infants who experienced significant hypoglycemia, regardless of apparent immediate outcome.

Special Populations

• Pediatric: Neonatal hypoglycemia is inherently a pediatric (newborn) condition. All previous sections are specifically tailored to this age group.

• Geriatric: Not applicable for neonatal hypoglycemia.

• Pregnancy: While the topic is neonatal, maternal conditions during pregnancy heavily influence neonatal hypoglycemia:

  • Maternal Diabetes: The primary risk factor for IDM, leading to fetal hyperinsulinemia. Management of maternal diabetes before and during pregnancy is critical for prevention.
  • Maternal Medications: Certain medications taken by the mother can affect fetal glucose regulation.

• Comorbidities:

  • Sepsis/Infection: Increases metabolic demand and can impair glucose production. Close monitoring and aggressive treatment of infection are crucial.
  • Perinatal Asphyxia: Leads to increased glucose utilization and impaired production due to hypoxic-ischemic insult. Often presents with severe, difficult-to-treat hypoglycemia.
  • Hypothermia: Increases glucose consumption due to shivering thermogenesis and non-shivering thermogenesis. Maintaining thermal neutrality is vital.
  • Polycythemia: Increased red blood cell mass increases glucose utilization. May require partial exchange transfusion in severe cases.
  • Inborn Errors of Metabolism: Require specific diagnostic tests and highly specialized management (e.g., dietary modification, specific enzyme cofactors/replacement).
  • Endocrine Deficiencies: Require specific hormone replacement (e.g., hydrocortisone for adrenal insufficiency, growth hormone for GH deficiency).

Clinical Pearls

• Diagnostic:

  • Asymptomatic is Common: Never rely solely on clinical signs; screening in at-risk infants is paramount.
  • Venous is Gold Standard: Always confirm low capillary blood glucose with a venous plasma glucose measurement.
  • "Critical Sample": For persistent hypoglycemia, draw blood for insulin, C-peptide, cortisol, GH, fatty acids, and ketones at the time of hypoglycemia before giving glucose to avoid masking the etiology.

• Treatment:

  • Early Feeding First: For asymptomatic at-risk infants with borderline low glucose, early and aggressive feeding (breast or formula) is the initial step.
  • Dextrose Bolus for Symptomatic/Critically Low: Do not delay IV dextrose if the infant is symptomatic or glucose is critically low (<20-25 mg/dL / 1.1-1.4 mmol/L).
  • Avoid Overtreatment/Rapid Correction: While rapid correction is needed, aim for a gradual return to euglycemia. Over-rapid correction or high glucose infusion rates can lead to rebound hyperglycemia and potential osmotic diuresis.
  • Consider Underlying Etiology: Don't just treat the number; always consider and investigate the underlying cause, especially for persistent or recurrent cases.

• Pitfalls:

  • Over-reliance on Capillary Glucose: Capillary heel stick values can be significantly different from plasma venous values.
  • Delayed Intervention: Waiting for symptoms in at-risk infants can lead to neurological damage.
  • Missing the Underlying Cause: Failure to investigate persistent hypoglycemia can lead to missed diagnoses of serious metabolic or endocrine disorders.
  • Discharging At-Risk Infants Prematurely: Ensure glucose stability for at least 24-48 hours after discontinuation of interventions before discharge.

Recent Updates

• Guidelines: The American Academy of Pediatrics (AAP) published a clinical report on "Management of Neonatal Hypoglycemia" in 2011, which remains a cornerstone. Subsequent reviews and consensus statements have largely reinforced these principles while acknowledging ongoing debates. There is an emphasis on evidence-based screening and intervention to balance preventing brain injury with avoiding over-medicalization.
• Evidence:
  • Ongoing research continues to refine optimal glucose thresholds and management strategies, particularly for asymptomatic infants. Some studies suggest that even prolonged mild-moderate hypoglycemia might have subtle neurodevelopmental consequences, though direct causality is difficult to prove.
  • Emphasis on early enteral feeding strategies to prevent hypoglycemia.
  • Increased recognition of congenital hyperinsulinism as a significant cause of persistent hypoglycemia and advances in its diagnosis and medical/surgical management.
• Controversies:
  • Optimal Glucose Thresholds: Debate continues regarding the precise "safe" lower limit of glucose concentration, especially for asymptomatic infants, and the duration below which these levels are harmful. Some clinicians advocate for a higher threshold for intervention to err on the side of caution.
  • Long-term Neurodevelopmental Outcomes: The extent of subtle neurodevelopmental deficits following asymptomatic or mild-moderate hypoglycemia is still an area of active research.

Key References

• Guidelines:

  • American Academy of Pediatrics. Clinical Report: Management of Neonatal Hypoglycemia. Pediatrics. 2011 Nov;128(5):e1254-66. (This is a foundational guideline).
  • Australasian Paediatric Endocrine Group (APEG) Consensus Guidelines for the Management of Hyperinsulinism in Infants and Children. J Paediatr Child Health. 2014 Aug;50(8):585-92.
  • NICE Guideline NG29: Diabetes in pregnancy: management from preconception to the postnatal period. National Institute for Health and Care Excellence. (Includes sections on neonatal hypoglycemia in IDM).

• Studies:

  • Boluyt N, et al. Neonatal Hypoglycemia and Neurologic Outcomes: A Meta-analysis. JAMA Pediatr. 2015 Mar;169(3):284-93.
  • Harris DL, et al. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, controlled trial. Lancet. 2013 Aug 31;382(9891):777-83. (Landmark study supporting oral dextrose gel).

• Reviews:

  • Adamkin DH. Neonatal hypoglycemia. Curr Opin Pediatr. 22:131-135, 2010.
  • Stanley CA, et al. The Diagnosis and Management of Congenital Hyperinsulinism. Neonatology. 2015;108(2):120-128.